Rozanski Alexander T, Zhang Lawrence T, Holst Daniel D, Copacino Steven A, Vanni Alex J, Buckley Jill C
Lahey Hospital and Medical Center, Burlington, MA.
Lahey Hospital and Medical Center, Burlington, MA.
Urology. 2021 Jan;147:294-298. doi: 10.1016/j.urology.2020.09.035. Epub 2020 Oct 6.
To assess the efficacy, effect of radiotherapy, and complications of direct visual internal urethrotomy (DVIU) and intralesional mitomycin C (MMC) for recurrent bladder neck contracture/vesicourethral anastomotic stenosis (BNC/VUAS).
Patients who underwent DVIU with intralesional MMC for recurrent BNC/VUAS between 2007 and 2019 at 2 institutions were included. Cold knife incisions were performed in a reproducible fashion followed by injection of 0.3-0.4 mg/mL MMC at each incision site. Those with evidence of complete urethral obliteration, stenosis of the entire posterior urethra, or <3 months follow-up were excluded. Success was defined as the ability to pass a 17-French cystoscope postoperatively without the need for catheterization or additional procedures.
Eighty-six patients were analyzed over a median follow-up of 21.1 months. Around 91% had at least 1 prior DVIU, 56% had at least 1 prior dilation, and 44% presented with an indwelling catheter or performed intermittent catheterization. Success was achieved in 65% after 1 procedure, an additional 18% after 2 procedures, and another 7% after 3 or more procedures (90% overall success rate). Nonradiated patients showed a higher overall success rate compared to radiated patients (94% vs 76%, P = 0.04). Of the 9 cystoscopic failures, 5 were asymptomatic and pursued observation. Only 2 (5%) patients with a history of catheterization required this postoperatively. Two patients underwent subsequent urinary diversion surgery. No long-term complications were seen.
DVIU with low-dose MMC remains a safe and effective BNC/VUAS treatment. A patent bladder neck was achieved in >90% of nonradiated patients and >75% of radiated patients.
评估直视下内部尿道切开术(DVIU)联合病灶内注射丝裂霉素C(MMC)治疗复发性膀胱颈挛缩/膀胱尿道吻合口狭窄(BNC/VUAS)的疗效、放疗效果及并发症。
纳入2007年至2019年期间在两家机构接受DVIU联合病灶内MMC治疗复发性BNC/VUAS的患者。采用可重复的方式进行冷刀切开,然后在每个切口部位注射0.3-0.4mg/mL的MMC。排除有尿道完全闭塞、整个后尿道狭窄或随访时间<3个月证据的患者。成功定义为术后能够通过17F膀胱镜且无需导尿或额外手术。
对86例患者进行了分析,中位随访时间为21.1个月。约91%的患者至少接受过1次先前的DVIU,56%的患者至少接受过1次先前的扩张,44%的患者留置导尿管或进行间歇性导尿。1次手术后成功率为65%,2次手术后额外成功率为18%,3次或更多次手术后再增加7%(总体成功率90%)。未接受放疗的患者总体成功率高于接受放疗的患者(94%对76%,P=0.04)。在9例膀胱镜检查失败的患者中,5例无症状并进行观察。只有2例(5%)有导尿史的患者术后需要导尿。2例患者随后接受了尿流改道术。未见长期并发症。
低剂量MMC的DVIU仍然是一种安全有效的BNC/VUAS治疗方法。>90%的未接受放疗患者和>75%的接受放疗患者实现了膀胱颈通畅。